Preclinical Pharmacokinetic Evaluation of beta-Lapachone: Characteristics of Oral Bioavailability and First-Pass Metabolism in Rats
Biomolecules & Therapeutics
;
: 296-300, 2015.
Article
in English
| WPRIM
| ID: wpr-178031
ABSTRACT
beta-Lapachone has drawn increasing attention as an anti-inflammatory and anti-cancer drug. However, its oral bioavailability has not been yet assessed, which might be useful to develop efficient dosage forms possibly required for non-clinical and clinical studies and future market. The aim of the present study was thus to investigate pharmacokinetic properties of beta-lapachone as well as its first-pass metabolism in the liver, and small and large intestines after oral administration to measure the absolute bioavailability in rats. A sensitive HPLC method was developed to evaluate levels of beta-lapachone in plasma and organ homogenates. The drug degradation profiles were examined in plasma to assess the stability of the drug and in liver and intestinal homogenates to evaluate first-pass metabolism. Pharmacokinetic profiles were obtained after oral and intravenous administration of beta-lapachone at doses of 40 mg/kg and 1.5 mg/kg, respectively. The measured oral bioavailability of beta-lapachone was 15.5%. The considerable degradation of beta-lapachone was seen in the organ homogenates but the drug was quite stable in plasma. In conclusion, we suggest that the fairly low oral bioavailability of beta-lapachone may be resulted from the first-pass metabolic degradation of beta-lapachone in the liver, small and large intestinal tracts and its low aqueous solubility.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Plasma
/
Solubility
/
Pharmacokinetics
/
Biological Availability
/
Administration, Oral
/
Chromatography, High Pressure Liquid
/
Dosage Forms
/
Administration, Intravenous
/
Intestines
/
Liver
Limits:
Animals
Language:
English
Journal:
Biomolecules & Therapeutics
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS